Structure Therapeutics (NASDAQ:GPCR) Price Target Lowered to $86.00 at JMP Securities

Structure Therapeutics (NASDAQ:GPCR) had its target price decreased by equities researchers at JMP Securities from $91.00 to $86.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ target price points to a potential upside of 154.66% from the company’s current price.

Other analysts also recently issued reports about the company. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, July 1st. Finally, BMO Capital Markets lifted their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $84.63.

Structure Therapeutics Trading Down 2.1 %

Shares of GPCR traded down $0.72 during trading hours on Friday, reaching $33.77. 769,472 shares of the company traded hands, compared to its average volume of 820,716. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -43.86 and a beta of -3.52. Structure Therapeutics has a 12-month low of $25.57 and a 12-month high of $75.02. The stock’s fifty day moving average price is $42.13 and its 200 day moving average price is $40.74.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, research analysts forecast that Structure Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently added to or reduced their stakes in the company. Sectoral Asset Management Inc. bought a new position in Structure Therapeutics in the fourth quarter worth about $139,000. ADAR1 Capital Management LLC bought a new position in Structure Therapeutics in the fourth quarter worth about $163,000. Mather Group LLC. bought a new position in Structure Therapeutics in the second quarter worth about $214,000. Raymond James & Associates bought a new position in Structure Therapeutics in the fourth quarter worth about $233,000. Finally, Gilbert & Cook Inc. bought a new position in Structure Therapeutics in the second quarter worth about $229,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.